Where are children ages 5-17 years receiving their COVID-19 vaccinations? Variations over time and by sociodemographic characteristics, United States

被引:8
|
作者
Santibanez, Tammy A. [1 ]
Black, Carla L. [1 ]
Vogt, Tara M. [1 ]
Chatham-Stephens, Kevin [4 ]
Zhou, Tianyi [1 ,3 ]
Lendon, Jessica P. [2 ]
Singleton, James A. [1 ]
机构
[1] Ctr Dis Control & Prevent CDC, Natl Ctr Immunizat & Resp Dis NCIRD, 1600 Clifton Rd NE, Atlanta, GA 30329 USA
[2] Ctr Dis Control & Prevent CDC, Natl Ctr Hlth Stat NCHS, 3311 Toledo Rd, Hyattsville, MD 20782 USA
[3] Leidos Inc, 2295 Parklake Dr NE, Atlanta, GA 30345 USA
[4] Ctr Dis Control & Prevent CDC, Natl Ctr Birth Defects & Dev Disabil NCBDDD, 1600 Clifton Rd NE, Atlanta, GA 30329 USA
关键词
COVID-19; Vaccination; Vaccination setting; Children; INFLUENZA VACCINATION; MEDICAL HOME; IMMUNIZATION PRACTICES; ADVISORY-COMMITTEE; COVERAGE; VACCINES;
D O I
10.1016/j.vaccine.2022.10.025
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background: Knowing the settings where children ages 5-17 years received COVID-19 vaccination in the United States, and how settings changed over time and varied by socio-demographics, is of interest for planning and implementing vaccination programs.Methods: Data from the National Immunization Survey-Child COVID-19 Module (NIS-CCM) were ana-lyzed to assess place of COVID-19 vaccination among vaccinated children ages 5-17 years. Interviews from July 2021 thru May 2022 were included in the analyses for a total of n = 39,286 vaccinated children. The percentage of children receiving their COVID-19 vaccine at each type of setting was calculated over-all, by sociodemographic characteristics, and by month of receipt of COVID-19 vaccine.Results: Among vaccinated children ages 5-11 years, 46.9 % were vaccinated at a medical place, 37.1 % at a pharmacy, 8.1 % at a school, 4.7 % at a mass vaccination site, and 3.2 % at some other non-medical place. Among vaccinated children ages 12-17 years, 35.1 % were vaccinated at a medical place, 47.9 % at a phar-macy, 8.3 % at a mass vaccination site, 4.8 % at a school, and 4.0 % at some other non-medical place. The place varied by time among children ages 12-17 years but minimally for children ages 5-11 years. There was variability in the place of COVID-19 vaccination by age, race/ethnicity, health insurance, urbanicity, and region. Conclusion: Children ages 5-17 years predominantly received their COVID-19 vaccinations at pharmacies and medical places. The large proportion of vaccinated children receiving vaccination at pharmacies is indicative of the success in the United States of expanding the available settings where children could be vaccinated. Medical places continue to play a large role in vaccinating children, especially younger children, and should continue to stock COVID-19 vaccine to keep it available for those who are not yet vaccinated, including the newly recommended group of children < 5 years.Published by Elsevier Ltd.
引用
收藏
页码:6917 / 6923
页数:7
相关论文
共 50 条
  • [31] An overview of the COVID-19 pediatric vaccine program - The US experience vaccinating children ages 6 months through 17 years
    Chatham-Stephens, Kevin
    Carter, Rosalind J.
    Duggar, Chris
    Woodworth, Kate R.
    Carnes, Catherine Amanda
    Bhatt, Achal
    Ottis, Christina
    Voegeli, Chris
    Stokley, Shannon
    Vogt, Tara
    VACCINE, 2024, 42
  • [32] Characteristics and Outcomes of Over 300,000 Patients with COVID-19 and History of Cancer in the United States and Spain
    Roel, Elena
    Pistillo, Andrea
    Recalde, Martina
    Sena, Anthony G.
    Fernandez-Bertolin, Sergio
    Aragon, Maria
    Puente, Diana
    Ahmed, Waheed-Ul-Rahman
    Alghoul, Heba
    Alser, Osaid
    Alshammari, Thamir M.
    Areia, Carlos
    Blacketer, Clair
    Carter, William
    Casajust, Paula
    Culhane, Aedin C.
    Dawoud, Dalia
    DeFalco, Frank
    DuVall, Scott L.
    Falconer, Thomas
    Golozar, Asieh
    Gong, Mengchun
    Hester, Laura
    Hripcsak, George
    Tan, Eng Hooi
    Jeon, Hokyun
    Jonnagaddala, Jitendra
    Lai, Lana Y. H.
    Lynch, Kristine E.
    Matheny, Michael E.
    Morales, Daniel R.
    Natarajan, Karthik
    Nyberg, Fredrik
    Ostropolets, Anna
    Posada, Jose D.
    Prats-Uribe, Albert
    Reich, Christian G.
    Rivera, Donna R.
    Schilling, Lisa M.
    Soerjomataram, Isabelle
    Shah, Karishma
    Shah, Nigam H.
    Shen, Yang
    Spotniz, Matthew
    Subbian, Vignesh
    Suchard, Marc A.
    Trama, Annalisa
    Zhang, Lin
    Zhang, Ying
    Ryan, Patrick B.
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2021, 30 (10) : 1884 - 1894
  • [33] A Cross-Sectional Study to Assess mRNA-COVID-19 Vaccine Safety among Indian Children (5-17 Years) Living in Saudi Arabia
    Ahsan, Marya
    Shaik, Riyaz Ahamed
    Mallick, Ayaz K.
    Banawas, Saeed S.
    Alruwaili, Thamer A. M.
    Alanazi, Yousef Abud
    Alzahrani, Hayat Saleh
    Ahmad, Ritu Kumar
    Ahmad, Mohammad Shakil
    AlAnazi, Faisal Holil
    Alfhaid, Fahad
    Aljulifi, Mohammed Zaid
    Mehta, Vini
    Almhmd, Abdalah Emad
    Al Daham, Abdulaziz S. D.
    Alruwaili, Mutlaq M. M.
    VACCINES, 2023, 11 (02)
  • [34] Safety of the BNT162b2 COVID-19 Vaccine in Children Aged 5 to 17 Years
    Hu, Mao
    Wong, Hui Lee
    Feng, Yuhui
    Lloyd, Patricia C.
    Smith, Elizabeth R.
    Amend, Kandace L.
    Kline, Annemarie
    Beachler, Daniel C.
    Gruber, Joann F.
    Mitra, Mahasweta
    Seeger, John D.
    Harris, Charlalynn
    Secora, Alex
    Obidi, Joyce
    Wang, Jing
    Song, Jennifer
    McMahill-Walraven, Cheryl N.
    Reich, Christian
    McEvoy, Rowan
    Do, Rose
    Chillarige, Yoganand
    Clifford, Robin
    Cooper, Danielle D.
    Shoaibi, Azadeh
    Forshee, Richard
    Anderson, Steven A.
    JAMA PEDIATRICS, 2023, 177 (07) : 710 - 717
  • [35] Investigating the relationships between concentrated disadvantage, place connectivity, and COVID-19 fatality in the United States over time
    Jing, Fengrui
    Li, Zhenlong
    Qiao, Shan
    Zhang, Jiajia
    Olatosi, Bankole
    Li, Xiaoming
    BMC PUBLIC HEALTH, 2022, 22 (01)
  • [36] Investigating the relationships between concentrated disadvantage, place connectivity, and COVID-19 fatality in the United States over time
    Fengrui Jing
    Zhenlong Li
    Shan Qiao
    Jiajia Zhang
    Bankole Olatosi
    Xiaoming Li
    BMC Public Health, 22
  • [37] Estimating pediatric cases of COVID-19 over time in the United States: Filling in a gap in public use data
    Wiemken, Timothy L.
    Niemotka, Samson L.
    Clarke, Jacob A.
    Prener, Christopher G.
    Rutschman, Ana Santos
    AMERICAN JOURNAL OF INFECTION CONTROL, 2022, 50 (01) : 4 - 7
  • [38] COVID-19 vaccine inquiries regarding children ages 5-11 years received by NIP-INFO
    Hall, Elisha
    Morales, Sarah
    Wolicki, JoEllen
    Schillie, Sarah
    PUBLIC HEALTH NURSING, 2022, 39 (05) : 1119 - 1122
  • [39] Spatio-temporal variations of night-time lights at early stages of the COVID-19 epidemic in the United States
    Xu G.
    Wang C.
    Meng Q.
    Xiu T.
    Li X.
    National Remote Sensing Bulletin, 2022, 26 (09) : 1777 - 1788
  • [40] Booster and Additional Primary Dose COVID-19 Vaccinations Among Adults Aged ≥65 Years - United States, August 13, 2021-November 19, 2021
    Fast, Hannah E.
    Zell, Elizabeth
    Murthy, Bhavini Patel
    Murthy, Neil
    Meng, Lu
    Scharf, Lynn Gibbs
    Black, Carla L.
    Shaw, Lauren
    Chorba, Terence
    Harris, LaTreace Q.
    MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT, 2021, 70 (50): : 1735 - 1739